Gurizzan Cristina, Pedersini Rebecca, Fornaro Carla, Sardini Chiara, Zamparini Manuel, Monteverdi Sara, Tovazzi Valeria, Cosentini Deborah, Dalla Volta Alberto, Baggi Alice, Turla Antonella, Di Mauro Pierluigi, Lorini Luigi, Laganà Marta, Bianchi Susanna, Grisanti Salvatore, Consoli Francesca, Conti Elisabetta, Bossi Paolo, Berruti Alfredo
Medical Oncology Unit, Department of Medical and Surgical Specialties, Radiological Sciences, and Public Health, University of Brescia at the Azienda Socio Sanitaria Territoriale (ASST)-Spedali Civili, Brescia, Italy.
Front Oncol. 2021 Oct 14;11:707346. doi: 10.3389/fonc.2021.707346. eCollection 2021.
To evaluate the efficacy of clinical triage of oncological patients for safe continuation of cancer therapy implemented during the first SARS-CoV-2 outbreak.
Between 25 February and 21 April 2020, patients attending the Medical Oncology Unit, Spedali Civili Hospital, Brescia (Italy) for cancer therapy underwent triage to identify those with no signs and symptoms suspicious for SARS-CoV-2 infection in which antineoplastic treatment could be continued as scheduled. Triage questions investigated common symptoms (e.g., fever, cough, dyspnea, anosmia, dysgeusia, headache, nasal congestion, conjunctival congestion, sore throat, diarrhea, nausea and vomiting); body temperature and pulse oximetry were also recorded. All patients were followed-up for overt SARS-CoV-2 through to 18 May 2020.
Overall, 1180 patients (median age 65 years) underwent triage during the study period. The most frequent primary malignances were breast (32%), gastrointestinal (18%), and lung (16.5%) cancer. Thirty-one (2.5%) presented with clinically evident SARS-CoV-2 infection and tested positive on nasopharyngeal swab testing and/or radiological imaging. Triage identified 69 (6%) grey zone patients with symptoms suspicious for SARS-CoV-2; 5 (7.2%) subsequently developed symptomatic disease. Neither the symptomatic nor the grey zone patients received their scheduled treatment; instead, they were referred for hospitalization or home quarantine.
Triage of oncological patients at our Unit provided for safe continuation of scheduled cancer treatment in 91.5% of patients during the initial SARS-CoV-2 outbreak.
评估在首次严重急性呼吸综合征冠状病毒2（SARS-CoV-2）疫情期间实施的肿瘤患者临床分诊对安全继续癌症治疗的疗效。
2020年2月25日至4月21日，在意大利布雷西亚市斯皮达利奇维利医院肿瘤内科接受癌症治疗的患者接受分诊，以确定那些没有SARS-CoV-2感染可疑体征和症状的患者，这些患者可以按计划继续进行抗肿瘤治疗。分诊问题调查了常见症状（如发热、咳嗽、呼吸困难、嗅觉丧失、味觉障碍、头痛、鼻塞、结膜充血、喉咙痛、腹泻、恶心和呕吐）；还记录了体温和脉搏血氧饱和度。所有患者均随访至2020年5月18日，以观察是否出现明显的SARS-CoV-2感染。
在研究期间，共有1180名患者（中位年龄65岁）接受了分诊。最常见的原发性恶性肿瘤是乳腺癌（32%）、胃肠道癌（18%）和肺癌（16.5%）。31名（2.5%）患者出现临床上明显的SARS-CoV-2感染，鼻咽拭子检测和/或影像学检查呈阳性。分诊识别出69名（6%）有SARS-CoV-2感染可疑症状的灰色地带患者；其中5名（7.2%）随后出现了有症状的疾病。有症状的患者和灰色地带的患者均未接受计划中的治疗；相反，他们被转诊住院或居家隔离。
在首次SARS-CoV-2疫情期间，我们科室对肿瘤患者进行分诊，使91.5%的患者能够安全地继续按计划进行癌症治疗。
